DCM
RNAC icon

Driehaus Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

Driehaus Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-17,167
Closed -$1.28M – 455
2020
Q3 		$1.28M Sell
17,167
-2,833
-14% -$217K 0.03% 274
2020
Q2 		$1.7M Buy
20,000
+11,667
+140% +$1.06M 0.04% 266
2020
Q1 		$603K Buy
+8,333
New +$805K 0.02% 290

Other funds holding RNAC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Driehaus Capital Management's RNAC Position: Q4 2020 in Review

Driehaus Capital Management sold out of Cartesian Therapeutics (RNAC) in Q4 2020, closing a stake of 17,167 shares — an estimated $1.28M sold.

Driehaus Capital Management first reported a position in RNAC in Q1 2020 and held it in 3 quarters. The position peaked at $1.7M in Q2 2020. 95 funds tracked by Wall St. Rank hold RNAC as of Q4 2020.

  • Driehaus Capital Management reported no remaining Cartesian Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Driehaus Capital Management sold 17,167 Cartesian Therapeutics shares in Q4 2020, an estimated $1.28M.
  • Driehaus Capital Management first reported a position in Cartesian Therapeutics in Q1 2020 and held it in 3 quarters.
  • Driehaus Capital Management's Cartesian Therapeutics position peaked at $1.7M in Q2 2020.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2020.

Based on Driehaus Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.